| 日付 | 受信時刻 | ニュースソース | 見出し | コード | 企業名 |
| 2023/12/22 | 05 : 32 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 2023/12/06 | 08 : 26 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 2023/12/02 | 01 : 49 | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 2023/11/17 | 06 : 55 | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 2023/10/24 | 02 : 56 | Edgar (US Regulatory) | Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 2023/10/06 | 10 : 01 | Business Wire | Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 2023/10/06 | 05 : 21 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 2023/09/16 | 04 : 42 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 2023/09/11 | 13 : 15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 2023/08/16 | 06 : 53 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 2023/08/12 | 05 : 06 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 2023/08/10 | 22 : 29 | Business Wire | Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 2023/08/09 | 05 : 23 | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 2023/07/31 | 22 : 32 | Business Wire | Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 2023/07/29 | 09 : 23 | Business Wire | Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 2023/07/29 | 06 : 10 | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 2023/07/28 | 06 : 20 | Business Wire | Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 2023/07/18 | 07 : 02 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 2023/07/18 | 07 : 00 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 2023/07/14 | 06 : 27 | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 2023/07/14 | 06 : 09 | Business Wire | Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 2023/07/07 | 05 : 39 | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 2023/07/04 | 06 : 30 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 2023/07/04 | 05 : 01 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 2023/07/01 | 05 : 01 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 2023/06/30 | 23 : 46 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 2023/06/30 | 23 : 46 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 2023/06/30 | 22 : 16 | Business Wire | Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 2023/06/17 | 06 : 23 | Edgar (US Regulatory) | Current Report Filing (8-k) | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 2023/06/17 | 06 : 00 | Edgar (US Regulatory) | Securities Registration (section 12(g)) (8-a12g) | AMEX:NAVB | Navidea Biopharmaceuticals Inc |